Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.
作者信息
Bürki Franck, Badie Kattalin, Bartoli Philippe, Bernard Pascale, Montastruc Jean Louis, Bagheri Haleh
出版信息
Br J Clin Pharmacol. 2008 May;65(5):793-4. doi: 10.1111/j.1365-2125.2008.03119.x. Epub 2008 Feb 15.
Abstract
摘要
相似文献
1
Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.
Br J Clin Pharmacol. 2008 May;65(5):793-4. doi: 10.1111/j.1365-2125.2008.03119.x. Epub 2008 Feb 15.
2
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
J Clin Oncol. 2011 Oct 1;29(28):e739-42. doi: 10.1200/JCO.2011.36.1865. Epub 2011 Sep 6.
3
Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
J Clin Oncol. 2012 Sep 10;30(26):e257-9. doi: 10.1200/JCO.2011.38.8942. Epub 2012 May 29.
4
Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
Clin Exp Ophthalmol. 2008 Jan-Feb;36(1):94-6. doi: 10.1111/j.1442-9071.2007.01658.x.
5
Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer.
World J Gastroenterol. 2014 Jun 7;20(21):6691-7. doi: 10.3748/wjg.v20.i21.6691.
6
Bevacizumab-associated osteonecrosis of the jaw.
Ann Oncol. 2008 Dec;19(12):2091-2. doi: 10.1093/annonc/mdn653. Epub 2008 Oct 31.
7
Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case.
Dis Colon Rectum. 2008 Sep;51(9):1425-6. doi: 10.1007/s10350-008-9282-8. Epub 2008 May 10.
8
[Posterior Reversible Encephalopathy Syndrome (PRES): About 4 cases].
Presse Med. 2019 Oct;48(10):1026-1031. doi: 10.1016/j.lpm.2019.08.019. Epub 2019 Oct 22.
9
Posterior reversible encephalopathy syndrome with bevacizumab.
Hong Kong Med J. 2011 Feb;17(1):80-1.
10
Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
Ann Hematol. 2010 Feb;89(2):207-8. doi: 10.1007/s00277-009-0783-x. Epub 2009 Jul 7.
引用本文的文献
1
Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review.
Front Pharmacol. 2023 Feb 6;14:1126235. doi: 10.3389/fphar.2023.1126235. eCollection 2023.
2
Atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer.
Case Rep Oncol Med. 2014;2014:391256. doi: 10.1155/2014/391256. Epub 2014 Oct 21.
3
Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.
Invest New Drugs. 2014 Oct;32(5):1036-45. doi: 10.1007/s10637-014-0113-6. Epub 2014 May 23.
4
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.
Target Oncol. 2011 Dec;6(4):253-8. doi: 10.1007/s11523-011-0201-x. Epub 2011 Nov 17.
5
Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrénées region (PharmacoMIP) network 2-year pilot study.
Drug Saf. 2010 May 1;33(5):409-16. doi: 10.2165/11319170-000000000-00000.
6
Looking back: editors' pick of 2008.
Br J Clin Pharmacol. 2009 Jan;67(1):1-4. doi: 10.1111/j.1365-2125.2008.03354.x.
本文引用的文献
1
Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
J Clin Oncol. 2007 Aug 10;25(23):3559. doi: 10.1200/JCO.2007.12.8710.
2
Hypertension as a predictive factor of Sunitinib activity.
Ann Oncol. 2007 Jun;18(6):1117. doi: 10.1093/annonc/mdm184.
3
Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma.
Onkologie. 2007 Mar;30(3):138-40. doi: 10.1159/000098706. Epub 2007 Feb 2.
4
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
Eur J Cancer. 2006 Dec;42(18):3127-39. doi: 10.1016/j.ejca.2006.09.015. Epub 2006 Nov 13.
5
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Arch Neurol. 2006 Oct;63(10):1475-8. doi: 10.1001/archneur.63.10.1475.
6
Reversible posterior leukoencephalopathy syndrome and bevacizumab.
N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2.
7
Reversible posterior leukoencephalopathy syndrome and bevacizumab.
N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2. doi: 10.1056/NEJMc052954.
8
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Nat Med. 2004 Feb;10(2):145-7. doi: 10.1038/nm988. Epub 2004 Jan 25.
9
Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma.
Ann Oncol. 2001 Sep;12(9):1327-9. doi: 10.1023/a:1012248800195.
Zotero 插件